Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Kratom single ascending dose in recreational polydrug users
NCT06072170Phase 1Completed
- Sponsor
- Altasciences
- Start
- Aug 2023
- Primary completion
- Jan 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ketum (6 arms), sponsored by Altasciences. Primary endpoint: Treatment-Emergent Adverse Events at 7 days. Started Aug 2023; status: completed.
02
Drugs
ketum
Beyond the preview
Go deeper on NCT06072170.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06072170.